Experimental and computational studies demonstrate new selenium adducts' anticancer potential in cancer cell lines, suggesting promising treatments.
The prepared compounds exhibited higher cytotoxicity against cancer cell lines than against normal cells. The results revealed that selenium adducts were more potent than their respective azolium salts. Among the test compounds, C₃ showed significant anticancer potential against both PC3 and HeLa cell lines with reasonably good IC₅₀ values of 5.75 ± 0.21 µM and 7.86 ± 0.12 µM, respectively. Theoretical studies, comprising molecular docking and DFT analysis, reinforced the experimental results and suggest that selenium adducts can be used as new anticancer agents.
No takes yet. Share an insight, caveat, or question.
Abbas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: